Anti-neuraminidase and Anti-hemagglutinin Immune Serum Can Confer Inter-lineage Cross Protection Against Recent Influenza B

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Jan 23

PMID 36689429

Authors

Joao Paulo Portela Catani

Tine Ysenbaert

Anouk Smet

Marnik Vuylsteke

Thorsten U Vogel

Xavier Saelens

Affiliations

Soon will be listed here.

Abstract

Influenza B viruses (IBV) are responsible for a considerable part of the burden caused by influenza virus infections. Since their emergence in the 1980s, the Yamagata and Victoria antigenic lineages of influenza B circulate in alternate patterns across the globe. Furthermore, their evolutionary divergence and the appearance of new IBV subclades complicates the prediction of future influenza vaccines compositions. It has been proposed that the addition of the neuraminidase (NA) antigen could potentially induce a broader protection and compensate for hemagglutinin (HA) mismatches in the current vaccines. Here we show that anti-NA and -HA sera against both Victoria and Yamagata lineages have limited inter-lineage cross-reactivity. When transferred to mice prior to infection with a panel of IBVs, anti-NA sera were as potent as anti-HA sera in conferring protection against homologous challenge and, in some cases, conferred superior protection against challenge with heterologous IBV strains.

Citing Articles

Seasonal influenza vaccines: Variability of immune responses to B lineage viruses.

Miller M, Montomoli E, Leshem E, Schotsaert M, Weinke T, Vicic N Hum Vaccin Immunother. 2024; 20(1):2421096.

PMID: 39552079 PMC: 11581161. DOI: 10.1080/21645515.2024.2421096.

Influenza B Virus Vaccine Innovation through Computational Design.

Pekarek M, Weaver E Pathogens. 2024; 13(9).

PMID: 39338946 PMC: 11434669. DOI: 10.3390/pathogens13090755.

Capsid virus-like particle display improves recombinant influenza neuraminidase antigen stability and immunogenicity in mice.

Kang H, Martinez M, Aves K, Okholm A, Wan H, Chabot S iScience. 2024; 27(6):110038.

PMID: 38883830 PMC: 11179578. DOI: 10.1016/j.isci.2024.110038.

References

Sheu T, Deyde V, Garten R, Klimov A, Gubareva L . Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res. 2009; 85(2):354-60. DOI: 10.1016/j.antiviral.2009.10.022. View

Madsen A, Dai Y, McMahon M, Schmitz A, Turner J, Tan J . Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective. Immunity. 2020; 53(4):852-863.e7. PMC: 7572813. DOI: 10.1016/j.immuni.2020.08.015. View

Koutsakos M, Wheatley A, Laurie K, Kent S, Rockman S . Influenza lineage extinction during the COVID-19 pandemic?. Nat Rev Microbiol. 2021; 19(12):741-742. PMC: 8477979. DOI: 10.1038/s41579-021-00642-4. View

Rossey I, Gilman M, Kabeche S, Sedeyn K, Wrapp D, Kanekiyo M . Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun. 2017; 8:14158. PMC: 5316805. DOI: 10.1038/ncomms14158. View

Sultana I, Yang K, Getie-Kebtie M, Couzens L, Markoff L, Alterman M . Stability of neuraminidase in inactivated influenza vaccines. Vaccine. 2014; 32(19):2225-30. DOI: 10.1016/j.vaccine.2014.01.078. View

Virk R, Jayakumar J, Mendenhall I, Moorthy M, Lam P, Linster M . Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc Natl Acad Sci U S A. 2019; 117(1):619-628. PMC: 6955377. DOI: 10.1073/pnas.1916585116. View

Piepenbrink M, Nogales A, Basu M, Fucile C, Liesveld J, Keefer M . Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells. mBio. 2019; 10(2). PMC: 6414695. DOI: 10.1128/mBio.00066-19. View

Chen Y, Wohlbold T, Zheng N, Huang M, Huang Y, Neu K . Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies. Cell. 2018; 173(2):417-429.e10. PMC: 5890936. DOI: 10.1016/j.cell.2018.03.030. View

Caini S, Kroneman M, Wiegers T, El Guerche-Seblain C, Paget J . Clinical characteristics and severity of influenza infections by virus type, subtype, and lineage: A systematic literature review. Influenza Other Respir Viruses. 2018; 12(6):780-792. PMC: 6185883. DOI: 10.1111/irv.12575. View

10.

Chen R, Holmes E . The evolutionary dynamics of human influenza B virus. J Mol Evol. 2008; 66(6):655-63. PMC: 3326418. DOI: 10.1007/s00239-008-9119-z. View

11.

Xu X, Lindstrom S, Shaw M, Smith C, Hall H, Mungall B . Reassortment and evolution of current human influenza A and B viruses. Virus Res. 2004; 103(1-2):55-60. DOI: 10.1016/j.virusres.2004.02.013. View

12.

Su S, Chaves S, Perez A, DMello T, Kirley P, Yousey-Hindes K . Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin Infect Dis. 2014; 59(2):252-5. DOI: 10.1093/cid/ciu269. View

13.

Oakley A, Barrett S, Peat T, Newman J, Streltsov V, Waddington L . Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem. 2010; 53(17):6421-31. PMC: 2932999. DOI: 10.1021/jm100621s. View

14.

Hoffmann E, Neumann G, Kawaoka Y, HOBOM G, Webster R . A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000; 97(11):6108-13. PMC: 18566. DOI: 10.1073/pnas.100133697. View

15.

Johansson B, Matthews J, KILBOURNE E . Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine. 1998; 16(9-10):1009-15. DOI: 10.1016/s0264-410x(97)00279-x. View

16.

McCullers J, Hoffmann E, Huber V, Nickerson A . A single amino acid change in the C-terminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and virulence. Virology. 2005; 336(2):318-26. PMC: 2737340. DOI: 10.1016/j.virol.2005.03.028. View

17.

Shang M, Blanton L, Brammer L, Olsen S, Fry A . Influenza-Associated Pediatric Deaths in the United States, 2010-2016. Pediatrics. 2018; 141(4). DOI: 10.1542/peds.2017-2918. View

18.

Ambrose C, Levin M . The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012; 8(1):81-8. PMC: 3350141. DOI: 10.4161/hv.8.1.17623. View

19.

Monto A, Petrie J, Cross R, Johnson E, Liu M, Zhong W . Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. J Infect Dis. 2015; 212(8):1191-9. DOI: 10.1093/infdis/jiv195. View

20.

McMahon M, Kirkpatrick E, Stadlbauer D, Strohmeier S, Bouvier N, Krammer F . Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs. mBio. 2019; 10(3). PMC: 6529633. DOI: 10.1128/mBio.00560-19. View